C.Q. Pharmaceutical Holding Co., Ltd. (SHE:000950)
5.92
+0.05 (0.85%)
May 8, 2026, 3:04 PM CST
SHE:000950 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 82,268 | 82,447 | 80,255 | 78,185 | 67,657 | 62,354 |
Other Revenue | - | - | 307.01 | 212.62 | 171.83 | 166.87 |
| 82,268 | 82,447 | 80,562 | 78,397 | 67,829 | 62,521 | |
Revenue Growth (YoY) | 0.88% | 2.34% | 2.76% | 15.58% | 8.49% | 38.26% |
Cost of Revenue | 76,411 | 76,507 | 74,641 | 72,162 | 62,038 | 56,817 |
Gross Profit | 5,857 | 5,940 | 5,921 | 6,235 | 5,791 | 5,703 |
Selling, General & Admin | 3,788 | 3,859 | 3,967 | 3,678 | 3,298 | 3,078 |
Research & Development | 0.76 | 0.47 | 0.32 | 0.38 | 3.24 | 10.04 |
Other Operating Expenses | 168.91 | 168.06 | 189.22 | 212.55 | 188.63 | 155.73 |
Operating Expenses | 3,958 | 4,027 | 4,688 | 4,279 | 3,614 | 3,526 |
Operating Income | 1,899 | 1,913 | 1,232 | 1,957 | 2,177 | 2,177 |
Interest Expense | - | - | -1,138 | -1,340 | -1,123 | -1,106 |
Interest & Investment Income | 464.47 | 415.48 | 488.19 | 393.27 | 355.29 | 347.92 |
Currency Exchange Gain (Loss) | - | - | -0.17 | 0.18 | 0.44 | -0.1 |
Other Non Operating Income (Expenses) | -1,543 | -1,535 | -41.03 | -103.03 | -12.36 | 3.66 |
EBT Excluding Unusual Items | 820.37 | 793.47 | 541.54 | 906.96 | 1,397 | 1,423 |
Impairment of Goodwill | - | - | -40.22 | -20.48 | -27.91 | -10.32 |
Gain (Loss) on Sale of Investments | -2.25 | -3.07 | 6.92 | 16.16 | 2.32 | 126.88 |
Gain (Loss) on Sale of Assets | 4.63 | 4.63 | 10.53 | 0.79 | 10.05 | 3.52 |
Asset Writedown | -116.95 | -123.17 | 0.01 | -0.01 | -0.02 | -0.35 |
Other Unusual Items | - | - | 38.73 | 62.91 | 91.25 | 37.35 |
Pretax Income | 705.81 | 671.86 | 557.51 | 966.33 | 1,472 | 1,580 |
Income Tax Expense | 158.62 | 150.53 | 155.72 | 236.04 | 309.5 | 289.61 |
Earnings From Continuing Operations | 547.19 | 521.33 | 401.79 | 730.29 | 1,163 | 1,291 |
Net Income to Company | 547.19 | 521.33 | 401.79 | 730.29 | 1,163 | 1,291 |
Minority Interest in Earnings | -114.98 | -134.61 | -118.8 | -105.65 | -210.72 | -285.23 |
Net Income | 432.21 | 386.72 | 282.99 | 624.63 | 952.28 | 1,005 |
Net Income to Common | 432.21 | 386.72 | 282.99 | 624.63 | 952.28 | 1,005 |
Net Income Growth | 41.58% | 36.65% | -54.69% | -34.41% | -5.29% | 13.69% |
Shares Outstanding (Basic) | 1,737 | 1,758 | 1,769 | 1,735 | 1,731 | 1,734 |
Shares Outstanding (Diluted) | 1,737 | 1,758 | 1,769 | 1,735 | 1,731 | 1,734 |
Shares Change (YoY) | -2.78% | -0.62% | 1.94% | 0.21% | -0.12% | 0.31% |
EPS (Basic) | 0.25 | 0.22 | 0.16 | 0.36 | 0.55 | 0.58 |
EPS (Diluted) | 0.25 | 0.22 | 0.16 | 0.36 | 0.55 | 0.58 |
EPS Growth | 45.63% | 37.50% | -55.56% | -34.54% | -5.17% | 13.73% |
Free Cash Flow | -716 | 455.13 | -437.27 | 264.13 | 17.76 | -239.38 |
Free Cash Flow Per Share | -0.41 | 0.26 | -0.25 | 0.15 | 0.01 | -0.14 |
Dividend Per Share | - | - | 0.060 | 0.050 | 0.060 | 0.105 |
Dividend Growth | - | - | 20.00% | -16.67% | -42.86% | - |
Gross Margin | 7.12% | 7.21% | 7.35% | 7.95% | 8.54% | 9.12% |
Operating Margin | 2.31% | 2.32% | 1.53% | 2.50% | 3.21% | 3.48% |
Profit Margin | 0.53% | 0.47% | 0.35% | 0.80% | 1.40% | 1.61% |
Free Cash Flow Margin | -0.87% | 0.55% | -0.54% | 0.34% | 0.03% | -0.38% |
EBITDA | 2,182 | 2,189 | 1,479 | 2,203 | 2,408 | 2,346 |
EBITDA Margin | 2.65% | 2.66% | 1.84% | 2.81% | 3.55% | 3.75% |
D&A For EBITDA | 282.95 | 275.68 | 246.6 | 246.87 | 231.17 | 169.06 |
EBIT | 1,899 | 1,913 | 1,232 | 1,957 | 2,177 | 2,177 |
EBIT Margin | 2.31% | 2.32% | 1.53% | 2.50% | 3.21% | 3.48% |
Effective Tax Rate | 22.47% | 22.41% | 27.93% | 24.43% | 21.02% | 18.33% |
Revenue as Reported | - | - | 80,562 | 78,397 | 67,829 | 62,521 |
Advertising Expenses | - | - | 9.42 | 9.57 | 20.39 | 23.49 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.